Synergia Medical develops implantable neuromodulation devices designed to treat drug-resistant epilepsy through vagus nerve stimulation. The company’s platform, NAO.VNS, is an optoelectronic, MRI-compatible stimulator engineered for chronic use with long battery life and rapid recharging capabilities. Its approach emphasizes safety, compatibility with diagnostic imaging, and reliable chronic therapy delivery. Synergia Medical positions its technology within regulated clinical and therapeutic care pathways.

The technology delivers controlled electrical stimulation to the vagus nerve via an implantable device, modulating neural circuits implicated in seizure activity. Optoelectronic components allow precise control of stimulation parameters while maintaining MRI compatibility for safe imaging follow-up. The system is designed for long-term implantation, with fast-charge functionality minimizing interruptions to therapy. This approach focuses on consistent, patient-tailored neuromodulation with minimal procedural burden.

Synergia Medical targets patients with epilepsy who have not responded adequately to pharmacological treatment. The NAO.VNS system is intended for use under professional clinical supervision in specialized care settings. Its positioning reflects broader interest in advanced vagus nerve stimulation technologies that combine safety, chronic reliability, and patient convenience.